Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Net Income towards Common Stockholders (2016 - 2025)

vTv Therapeutics' Net Income towards Common Stockholders history spans 12 years, with the latest figure at -$7.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 96.42% year-over-year to -$7.1 million; the TTM value through Dec 2025 reached -$27.0 million, down 46.11%, while the annual FY2025 figure was -$27.0 million, 46.11% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$7.1 million at vTv Therapeutics, up from -$8.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$841000.0 in Q2 2021 and bottomed at -$8.7 million in Q3 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$5.0 million (2024), against an average of -$5.0 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 83.15% in 2021 against a maximum downside of 538.77% in 2021.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$7.1 million in 2021, then surged by 32.7% to -$4.7 million in 2022, then rose by 26.7% to -$3.5 million in 2023, then dropped by 4.49% to -$3.6 million in 2024, then plummeted by 96.42% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Net Income towards Common Stockholders are -$7.1 million (Q4 2025), -$8.7 million (Q3 2025), and -$6.0 million (Q2 2025).